Reviewing the use of antipsychotic drugs in people with intellectual disability

Human Psychopharmacology

Volumn 21, Issue 2, 2006, Pages 73-89

  La Malfa, Giampaolo ^a,b   Lassi, Stefano ^a   Bertelli, Marco ^a   Castellani, Alessandro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NONE   (Italy)

Author keywords

Antipsychotics; Intellectual disability; Review

Indexed keywords

AMISULPRIDE; BENPERIDOL; BROMPERIDOL; CHLORPROMAZINE; CLOTIAPINE; CLOZAPINE; DROPERIDOL; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PIPOTIAZINE; PLACEBO; PROMAZINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIAPRIDE; TRIFLUPERIDOL; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

AGRANULOCYTOSIS; AKATHISIA; ANGIONEUROTIC EDEMA; AUTISM; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DEMENTIA; DRUG EFFICACY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GOLD STANDARD; HEADACHE; HUMAN; HYPERSALIVATION; HYPOTHERMIA; INTELLECTUAL IMPAIRMENT; LEARNING DISORDER; LEUKOPENIA; MEDLINE; MENTAL DEFICIENCY; META ANALYSIS; METABOLIC DISORDER; NEUTROPENIA; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RELIABILITY; REVIEW; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TACHYCARDIA; THYROID DISEASE; TONGUE DISEASE; TREATMENT OUTCOME; VALIDATION PROCESS; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; RANDOMIZED CONTROLLED TRIALS;

EID: 33644616153     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.748     Document Type: Review

References (200)

1. AAMR, Aman MG, Alvarez N, Benefield W, Crismon ML, Green G, King BH, Reiss S, Rojahn J, Szymanski L. 2000. Expert Consensus Guideline Series. Treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retard 105: 159-226.
2. Abbott P, Blake A, Vincze L. 1965. Treatment of mentally retarded with thioridazine. Dis Nerv Syst 26(9): 583-585.
3. Advokat CD, Mayville EA, Matson JL. 2000. Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Res Dev Disabil 21(1): 75-84.
4. Album MM. 1960. Dental use of meprobamate and promazine hydrochloride for mentally retarded and emotionally disturbed patients: a preliminary report. Oral Surg Oral Med Oral Pathol 13: 423-426.
5. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. 2002. Risperidone disruptive behavior study group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159(8): 1337-1346.
6. Aman MG, Gharabawi GM, Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients with Mental Retardation and Developmental Disabilities. 2004. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. J Clin Psychiatry 65(9): 1197-1210.
7. Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN. 1991a. Methylphenidate and thioridazine in the treatment of intellectually subaverage children: effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry 30(5): 816-824.
8. Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN. 1991b. Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 30(2): 246-256.
9. Aman MG, White AJ, Field C. 1984. Chlorpromazine effects on stereotypic and conditioned beahavior of severely retarded patients - A pilot study. J Ment Defic Res 28(4): 253-260.
10. Aman MG, White AJ. 1988. Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents. J Autism Dev Disord 18(3): 355-366.
11. Aman MG. 1993. Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities. Ann Clin Psychiatry 5(3): 171-188.
12. Antonacci DJ, de Groot CM. 2000. Clozapine treatment in a population of adults with mental retardation. J Clin Psychiatry 61(1): 22-25.
13. Archer T. 1993. Behavioural retardation in the neuropathology of mental retardation. APMIS Suppl 40: 35-56.
14. Asan A, Knobel G, Stene-Larsen G. 1986. Experiences with the use of levomepromazine and diazepam as premedication for dental treatment of the mentally handicapped. Nor Tannlaegeforen Tid 96(6): 259-261.
15. Baghdadli A, Gonnier V, Aussilloux C. 2002. Review of psychopharmacological treatments in adolescents and adults with autistic disorders. Encephale 28(3): 248-254.
16. Bambrick M, Wilson DA. 1992. Recurrent neuroleptic malignant syndrome in a man with mild mental handicap. J Intellect Dis Res 36(4): 377-381.
17. Bokszanska A, Martin G, Vanstraelen M, Holt G, Bouras N, Taylor D. 2003. Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study. Int Clin Psychopharmacol 18(5): 285-291.
18. Bouras N, Bridges PK, Brooks D. 1986. Clopenthixol in aggressive mentally handicapped patients. Br J Psychiatry 149: 795.
19. Boyd RD. 1992. Recurrence of neuroleptic malignant syndrome via an inadvertent rechallenge in a woman with mental retardation. Ment Retard 30(2): 77-79.
20. Branford D, Collacott RA, Thorp C. 1995. The prescribing of neuroleptic drugs for people with learning disabilities living in Leicestershire. J Intellect Disabil Res 39(6): 495-500.
21. Branford D. 1996. A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. J Intellect Disabil Res 40(4): 358-368.
22. Brasic JR, Barnett JY. 1997. Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. Psychol Rep 80(1): 163-170.
23. Breuning SE, Davis VJ, Matson JL, Ferguson DG. 1982. Effects of thioridazine and withdrawal dyskinesias on workshop performance of mentally retarded young adults. Am J Psychiatry 139(11): 1447-1454.
24. Breuning SE, Ferguson DG, Davidson NA, Poling AD. 1983. Effects of thioridazine on the intellectual performance of mentally retarded drug responders and nonresponders. Arch Gen Psychiatry 40(3): 309-313.
25. Brown TM. 1999. Clozapine, neuroleptic malignant syndrome, and pancerebellar syndrome. Psychosomatics 40(6): 518-520.
26. Brylewski J, Duggan L. 1999. Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials. J Intellect Disabil Res 43(5): 360-371.
27. Buck JA, Sprague RL. 1989. Psychotropic medication of mentally retarded residents in community long-term care facilities. Am J Ment Retard 93(6): 618-623.
28. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT. 2001. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62(4): 239-248.
29. Buitelaar JK. 1993. Self-injurious behaviour in retarded children: clinical phenomena and biological mechanisms. Acta Paedopsychiatr 56(2): 105-115.
30. Buitelaar JK. 2000. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive. J Child Adolesc Psychopharmacol Spring 10(1): 19-26.
31. Burk HW, Menolascino FJ. 1968. Haloperidol in emotionally disturbed mentally retarded individuals. Am J Psychiatry 124(11): 1589-1591.
32. Burness FR. 1968. Fluphenazine ('anatensol') in the treatment of disturbed mentally retarded children. Med J Aust 1(6): 241.
33. Burns ME. 1980. Droperidol in the management of hyperactivity, self-mutilation and aggression in mentally handicapped patients. J Int Med Res 8(1): 31-33.
34. Buzan RD, Dubovsky SL, Firestone D, Dal Pozzo E. 1998. Use of clozapine in 10 mentally retarded adults. J Neuropsychiatry Clin Neurosci Winter 10(1): 93-95.
35. Carrel R, Binns WH Jr, Chialastri AL 1977. Behavior modification of mentally retarded dental patients. Anesth Prog 24(3): 67-71.
36. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. 2004. Second-generation antipsycholic medications in children and adolescents. J Child Adolesc PsychopharmacolFall 14(3): 372-394.
37. Clarke M, Oxman AD. 2001. Cochrane Reviewers' Handbook 4.1.4 [updated October 2001]. In The Cochrane Library, Issue 4. Update Software: Oxford.
38. Cohen S, Fitzgerald B, Okos A, Khan S, Khan A. 2003. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 64(1): 60-62.
39. Cohen S, Glazewski R, Khan S, Khan A. 2001. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J Clin Psychiatry 62(2): 114-116.
40. Cohen SA, Underwood MT. 1994. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry 55(10): 440-444.
41. Coleman E, Siributr P, Leelamanit V, Tapanya S. 1993. The treatment of fetishism and socially inappropriate sexual behavior in a young male with dull normal intelligence hallucinations and erotomanic delusions in a mentally handicapped woman. J Med Assoc Thai 76(9): 531-546.
42. Conley RR, Kelly DL. 2002. Current status of antipsycbotic treatment. Curr Drug Target CNS Neurol Disord 1(2): 123-128.
43. Cooper SA. 1997. Psychiatry of elderly compared to younger adults with intellectual disability. J Appl Res Intellect Disabil 10(4): 303-311.
44. Coppola G, Morelli E, Bravaccio C, Federico R, Gritti A. 2004. Unusual compulsive motor activity during treatment with clothiapine in a mentally retarded adolescent. Brain Dev 26(6): 409-411.
45. Crews WD, Bonaventura. S, Hay CL, Steele WK, Rowe FB. 1993. Gilles de la Tourette disorder among individuals with severe or profound mental retardation. Ment Retard 31(1): 25-28.
46. Dartnall NA, Holmes JP, Morgan SN, McDougle. 1999. Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord 29(1): 87-91.
47. Deb S. 2001. Epidemiology of psychiatric illness in adults with intellectual disability. In Health Evidence Bullettin-Learning Disabilities (Intellectual Disability), Hamilton-Kirkward L, Ahmed Z, Deb S (eds). NHS: Cardiff; 14-17.
48. Demb HB. 1996. Risperidone in young children with pervasive developmental disorders and other developmental disabilities. J Child Adolesc Psychopharmacol Spring 6(1): 79-80.
49. Dent J. 1995. Catatonic syndrome following recovery from neuroleptic malignant syndrome. J Intellect Disabil Res 39(5): 457-459.
50. Diamond AW, Cochrane DF. 1976. General anaesthesia for the mentally handicapped: a study based on anaesthesia for dental surgery. Anaesthesia 31(2): 190-194.
51. Diamond JM, Hayes DD. 1986. A case of neuroleptic malignant syndrome in a mentally retarded adolescent. J Adolesc Health Care 7(6): 419-422.
52. Diler RS, Yolga A, Avci A, Scahill L. 2003. Risperidone-induced obsessive-compulsive symptoms in two children. J Child Adolesc Psychopharmacol 13(Suppl. 1): 89-92.
53. Dobbs RL, Brahm NC, Fast G, Brown RC. 2004. Thyroid function alterations following quetiapine initiation in a developmentally disabled adolescent. Ann Pharmacother 38(9): 1541-1542.
54. Dollfus S, Petit M, Menard JF, Lesieur P. 1992. Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. J Autism Dev Disord 22(1): 47-60.
55. Doody GA, Johnstone EC, Sanderson TL, Cunningham Owens DG, Muir WJ. 1998. 'Propfschizophrenie' revisited: Schizophrenia in people with mild learning disability. Br J Psychiatry 173: 145-153.
56. Dosen A, Day K (ed.). 2001. Treating Mental Illness and Behavior Disorders in Children and Adults with Mental Retardation. American Psychiatric Press Inc: Washington DC, London.
57. Duggan L, Brylewski J. 1999. Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review. J Intellect Disabil Res 43(2): 94-104.
58. Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J. 2000. Risperidone in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 39(5): 545-546.
59. Ernst M, Magee HJ, Gonzalez NM, Locascio JJ, Rosenberg CR, Campbell M. 1992. Pimozide in autistic children. Psychopharmacol Bull 28(2): 187-191.
60. Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. 1998. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 39(8): 874-877.
61. Fava M. 1997. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 20(2): 427-451.
62. Franco MA, Herraiz M, Martinez MJ, Fernandez MC, Conde V. 2000. Risperidone in the treatment of psychotic disorders associated with mental retardation. Actas Esp Psiquiatr 28(4): 251-256.
63. Friedlander R, Lazar S, Klancnik J. 2001. Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Can J Psychiatry 46(8): 741-745.
64. Galvin PM, Knezek LD, Rush AJ, Toprac MG, Johnson B. 1999. Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clin Ther 21(6): 1105-1116.
65. Garnier Y. 1978. The treatment with tiparide of the agitation and aggressivity of oligophrenic patients. Sem Hop 54(37-40): 1149-1150.
66. Gedye A. 1998. Neuroleptic-induced dementia documented in four adults with mental retardation. Ment Retard 36(3): 182-186.
67. Gelly F, Chambon O, Marie-Cardine M. 1997. Long-term clinical experience with clozapine. Encephale 23(5): 385-396.
68. Ghaziuddin M, Tsai LY, Ghaziuddin N. 1991. Brief report: haloperidol treatment of trichotillomania in a boy with autism and mental retardation. J Autism Dev Disord 21(3): 365-371.
69. Glanville J. 1999. Carrying out the literature search. In Clinical Research in Psychiatry: A Practical Guide, Curran S, Williams CJ (eds). Butterworth-Heinemann: Oxford; 57-58.
70. Glazer WM. 1997. Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry 58(Suppl. 10): 18-21.
71. Gothelf D, Frisch A, Munitz H, et al. 1999. Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome. Schizophr Res 35(2): 105-112.
72. Grabowski SW. 1973. Safety and effectiveness of haloperidol for mentally retarded behaviorally disordered and hyperkinetic patients. Curr Ther Res Clin Exp 15(11): 856-861.
73. Greenberg SB, Faerber EN, Radke JL, Aspinall CL, Adams RC, Mercer-Wilson DD. 1994. Sedation of difficult-to-sedate children undergoing MR imaging: value of thioridazine as an adjunct to chloral hydrate. Am J Roentgenol 163(1): 165-168.
74. Gross EJ, Hull HG, Lytton GJ, Hill JA, Piersel WC. 1993. Case study of neuroleptic-induced akathisia: important implications for individuals with mental retardation. Am J Ment Retard 98(1): 156-164.
75. Gualtieri CT, Lefler WH, Guimond M, Staye JL. 1982. Corneal and lenticular opacities in mentally retarded young adults treated with thioridazine and chlorpromazine. Am J Psychiatry 139(9): 1178-1180.
76. Haegeman J, Duyck F. 1978. A retrospective evaluation of pipamperone (Dipiperon) in the treatment of behavioural deviations in severely mentally handicapped. Acta Psychiatr Belg 78(2): 392-398.
77. Hal V, Feher L. 2004. Experience with Risperidone in the treatment of institutionalized retarded patients, with special reference to treatment of aggressive states. Neuropsychopharmacol Hung 6(1): 19-25.
78. Hammock R, Levine WR, Schroeder SR. 2001. Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation. J Autism Dev Disord 31(1): 109-113.
79. Hanzel TE, Bauemfeind JD, Kalachnik JE, Harder SR. 2000. Results of barbiturate antiepileptic drug discontinuation on anti-psychotic medication dose in individuals with intellectual disability. J Intellect Dis Res 44(2): 155-163.
80. Hanzel TE, Kalachnik JE, Harder SR. 1992. A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. Res Dev Disabil 13(4): 381-392.
81. Hassler F, Buchmann J, Bohne S. 2002. Possibilities and limits of treatment of aggressive behavior in patients with mental retardation with risperidone. Nervenarzt 73(3): 278-282.
82. Hassler F, Fegert JM. 1999. Psychopharmacological therapy of self-injurious behavior in mentally retarded individuals. Nervenarzt 70(11): 1025-1028.
83. Heistad GT, Zimmerman RL, Doebler MI. 1982. Long-term usefulness of thioridazine for institutionalized mentally retarded patients. Am J Ment Defic 87(3): 243-251.
84. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR. 2001. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol Fall 11(3): 229-238.
85. Hess-Rover J, Crichton J, Byme K, Holland AJ. 1999. Diagnosis and treatment of a severe psychotic illness in a man with dual severe sensory impairments caused by the presence of Usher syndrome. J Intellect Dis Res 43(5): 428-434.
86. Hill BK, Balow EA, Bruininks RH. 1985. A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacol Bull 21(2): 279-284.
87. Holden B, Gitlesen JP. 2004. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil 25(6): 509-521.
88. Holzer JC,Jacobson SA, Folstein ME 1996. Treating compulsive self-mutilation in a mentally retarded patient. Am J Psychiatry 153(1): 133.
89. Horrigan JP, Barnhill LJ. 1997. Risperidone and explosive aggressive autism. J Autism Dev Disord 27(3): 313-323.
90. Hove O. 2004. Prevalence of eating disorders in adults with mental retardation living in the community. Am J Ment Retard 109(6): 501-506.
91. Howland RH. 1996. Chlorpromazine and obsessive-compulsive symptoms. Am J Psychiatry 153(11): 1503.
92. Hurley AD, Folstein M, Lam N. 2003. Patients with and without intellectual disability seeking outpatient psychiatric services: diagnoses and prescribing pattern. J Intellect Disabil Res 47(1): 39-50.
93. Jagadheesan K, Nizamie SH. 2002. Risperidone-induced Pisa syndrome. Aust N Z J Psychiatry 36(1): 144.
94. Janowsky DS, Barnhill LJ, Davis JM. 2003. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry 64(10): 1258-1265.
95. John S, Ovsiew F. 1996. Erotomania in a brain-damaged male. J Intellect Dis Res 40(3): 279-283.
96. Jordan JAB. 1994. Use of a revised version of the psychotropic medication efficacy graph. Ment Retard 32(2): 128-131.
97. Kaplitz SE. 1966. The use of perphenazine syrup in the severely disturbed mentally retarded child. IMJ Ill Med J 130(6): 785-787.
98. Karsten D, Kivimaki T, Linna SL, Pollari L, Turunen S. 1981. Neuroleptic treatment of oligophrenic patients. A double-blind clinical multicentre trial of cis(Z)-clopenthixol and haloperidol. Acta Psychiatr Scand Suppl 294: 39-45.
99. Khan BU. 1997. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. J Autism Dev Disord 27(4): 479-489.
100. Kiernan C, Reeves D, Alborz A. 1995. The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour. J Intellect Dis Res 39(4): 263-274.
101. Konarski EA, Sutton K, Huffman A. 1997. Personal characteristics associated with episodes of injury in a residential facility. Am J Ment Retard 102(1): 37-44.
102. Krishnamoorthy J, King BH. 1998. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol 8(2): 107-113.
103. Lang C, Remington D. 1994. Treatment with propranolol of severe self-injurious behavior in a blind, deaf, retarded adolescent. J Am Acad Child Adolesc Psychiatry 33(2): 265-269.
104. Laveck GD, De la Cruz F, Simundson E. 1960. Fluphenazine in the treatment of mentally retarded children with behavior disorders. Dis Nerv Syst 21: 82-85.
105. Le Vann LJ. 1971. Clinical comparison of haloperidol with chlorpromazine in mentally retarded children. Am J Ment Defic 75(6): 719-723.
106. Linscheid TR, Landau RJ. 1993. Going 'all out' pharmacologically? A re-examination of Berkman and Meyer's 'alternative strategies and multiple outcomes in remediation of severe self-injury: going "all out" nonaversively'. Ment Retard 31(1): 7-14.
107. Lott RS, Kerrick JM, Cohen SA. 1996. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull 32(4): 721-729.
108. Loupe PS, Schroeder SR, Tessel RE. 1997. Effects of neuroleptic and anticonvulsant drugs on repeated acquisition learning in microencephalic and normal rats Exp Clin Psychopharmacol 5(4): 323-333.
109. Lynch DM, Eliatamby CL, Anderson AA. 1985. Pipothiazine palmitate in the management of aggressive mentally handicapped patients. Br J Psychiatry 146: 525-529.
110. Mace FC, Blum NJ, Sierp BJ, Delaney BA, Mauk JE. 2001. Differential response of operant self-injury to pharmacologic versus behavioral treatment. J Dev Behav Pediatr 22(2): 85-91.
111. Maier U, Aigner JM, Klein HE. 1994. Hypothermia caused by neuroleptics. 2 case reports and review of the literature. Nervenarzt 65(7): 488-491.
112. Malt UF, Nystad R, Bache T, et al. 1995. Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients. Br J Psychiatry 166(3): 374-377.
113. Maneeton N, Intaprasert S, Srisurapanont M. 2001. Risperidone for controlling aggressive behavior in a mentally retarded child: a case report. J Med Assoc Thai 84(6): 893-896.
114. Margolese HC, Chouinard G. 1999. Olanzapine-induced neuroleptic malignant syndrome with mental retardation. Am J Psychiatry 156(7): 1115-1116.
115. Marshall D, McConkey R, Moore G. 2003. Obesity in people with intellectual disabilities: the impact of nurse-led health screenings and health promotion activities. Adv Nurs 41(2): 147-153.
116. Martin A, Koenig K, Scahill L, Bregman J. 1999. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9(2): 99-107.
117. Matson JL, Bamburg JW, Mayville EA, et al. 2000. Psychopharmacology and mental retardation: a 10 year review (1990-1999). Res Dev Disabil 21(4): 263-269.
118. Matson JL, Bielecki J, Mayville SB, Matson ML. 2003. Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions. Res Dev Disabil 24(3): 149-157.
119. May P, London EB, Zimmerman T, Thompson R, Mento T, Spreat S. 1995. A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Ann Clin Psychiatry 7(4): 155-160.
120. McDonough M, Hillery J, Kennedy N. 2000. Olanzapine for chronic, stereotypic self-injurious behaviour: a pilot study in seven adults with intellectual disability. J Intellect Disabil Res 44(6): 677-684.
121. McDougle CJ, Holmes JP, Bronson MR, et al. 1997. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 36(5): 685-693.
122. McGillivray JA, McCabe MP. 2004. Pharmacological management of challenging behavior of individuals with intellectual disability. Res Dev Disabil 25(6): 523-537.
123. McGuire BE, Akuffo, E, Choon GL. 1994. Somatic sexual hallucinations and erotomanic delusions in a mentally handicapped woman. J Intellect Disabil Res 38(1): 79-83.
124. McNally RJ, Calamari JE. 1988. Neuroleptic malignant syndrome in a man with mental retardation. Ment Retard 26(6): 385-386.
125. Mikkelsen EJ. 1986. Low-dose haloperidol for stereotypic, self-injurious behavior in the mentally retarded. 1986. N Engl J Med 315(6): 398-399.
126. Mlele TJ, Wiley YV. 1986. Clopenthixol decanoate in the management of aggressive mentally handicapped patients. Br J Psychiatry 149: 373-376.
127. Morant A, Mulas F, Hernandez S, Rosello B. 2001. Pharmacological treatment with risperidone in children with behavior disorders. Rev Neurol 33(3): 201-208.
128. Moss S, Emerson E, Kiernan C, Turner S, Hatton C, Alborz A. 2000. Psychiatric symptoms in adults with learning disability and challenging behaviour. Br J Psychiatry 177: 452-456.
129. Naylor CD. 1985. Grey zone in clinical pratice: some limits to evidence-based medicine. Lancet 345: 840-842.
130. Neu P, Seyfert S, Brockmoller J, Dettling M, Marx P. 2002. Neuroleptic, malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency. Pharmacopsychiatry 35(1): 26-28.
131. NES Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. (CRD Report 4 2nd Edition). NHS Centre for Reviews and Dissemination: York, 2001.
132. Nottestad JA, Linaker OM. 2003. Psychotropic drug use among people with intellectual disability before and after deinstitutionalization. J Intellect Disabil Res 47(6): 464-471.
133. Oettinger B. 1976. Psychotropic drugs for behavior disorder treatment in oligophrenic epileptics. Psychiatr Neurol Med Psychol (Leipz) 28(10): 635-640.
134. Olson DA, Ingram W, Mann JR. 2002. Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation. J Clin Psychopharmacol 22(5): 529-530.
135. Ono Y. 1998. Behavior disorders in persons with mental retardation receiving antipsychotic medication. Res Dev Disabil 19(2): 123-130.
136. Pantanowitz L, Berk M. 1999. Auto-amputation of the tongue associated with flupenthixol induced extrapyramidal symptoms. Int, Clin Psychopharmacol 14(2): 129-131.
137. Pary RJ. 1994. Clozapine in three individuals with mild mental retardation and treatment-refractory psychiatric disorders. Ment Retard 32(5): 323-327.
138. Pedrosa Gil F, Schneider C, Grohmann R, Ruther E. 2001. Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy. Nervenarzt 72(11): 878.
139. Perry R, Pataki C, Munoz-Silva DM, Armenteros J, Silva R. 1997. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 7(3): 167-179.
140. Pirovino M, Meier J, Meyer M, Waldmeier P, Schmid M. 1984. Malignant neuroleptics syndrome. Dtsch Med Wochenschr 109(10): 378-381.
141. Purdon SE, Lit W, Labelle A, Jones BD. 1994. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 39(7): 400-405.
142. Rao JM, Cowie VA, Mathew B. 1989. Neuroleptic-induced parkinsoman side effects in the mentally handicapped. J Ment Defic Res 33(1): 81-86.
143. Rascati KL, Rascati EJ. 1993. Use of clozapine in Texas state mental health facilities. Am J Hosp Pharm 50(8): 1663-1666.
144. Read SG, Batchelor DH. 1986. Violent and self-injurious behaviour in mentally handicapped patients-psychopharmacological control. Int Clin Psychopharmacol 1(Suppl. 1): 63-74.
145. Reid WH, Mason M, Toprac M. 1994. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 45(3): 261-264.
146. Reid WH. 1994. The treatment of psychosis: resetting the drug cost 'thermostat'. J Clin Psychiatry 55(Suppl. B): 166-168.
147. Rosenquist PB, Bodfish JW, Thompson R. 1997. Tourette syndrome associated with mental retardation: a single-subject treatment study with haloperidol. Am J Ment Retard 101(5): 497-504.
148. Rowley JD, Kaplitz SE, Schwartz ML. 1959. The use of chlorpromazine in disturbed mentally retarded children. Ill Med J 116(2): 81-83.
149. Rubin M, Langa A. 1995. Clozapine, mental retardation, and severe psychiatric illness: clinical response in the first year. Harv Rev Psychiatry 2(5): 293-294.
150. Sackett DL, Strass SE, Rosenberg W, Haynes RB (eds). 2000. Evidence-based medicine. How to Practice and Teach EBM, 2nd edn. Churchill Livingston: London.
151. Sajatovic M, Ramirez LF, Kenny JT, Meltzer HY. 1994. The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. Compr Psychiatry 35(1): 29-33.
152. Schiller H. 1959. Reserpine, chlorpromazine and the mentally retarded. A report on 139 cases. Psychiatr Q 33: 683-699.
153. Schwaninger M, Weisbrod M, Schwab S, Schroder M, Hacke W. 1998. Hypothermia induced by atypical neuroleptics. Clin Neuropharmacol 21(6): 344-346.
154. Schweitzer I. 2001. Does risperidone have a place in the treatment of nonschizophrenic patients? Int Clin Psychopharmacol 16(1): 1-19.
155. Searcy E. 2001. Helping the patient who has pervasive developmental disorder. JAAPA 14(10): 39-41, 44-45.
156. Shedlack KJ, Levesque C, Charlot L, et al. 2003. Nothing new under the sun: clozapine rechallenge following a life-threatening medical event in a patient with psychiatric illness and developmental disability. Harv Rev Psychiatry 11(6): 344-352.
157. Simeon J, Milin R, Walker S. 2002. Retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 26(2): 267-275.
158. Simon EW, Blubaugh KM, Pippidis M. 1996. Substituting traditional antipsychotics with risperidone for individuals with mental retardation. Ment Retard 34(6): 359-366.
159. Singh I, Owino WJ. 1992. A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders. J Intellect Dis Res 36(6): 541-549.
160. Singh NN, Aman MG. 1981. Effects of thioridazine dosage on the behavior of severely mentally retarded persons. Am J Ment Defic 85(6): 580-587.
161. Singh NN, Landrum TJ, Ellis CR, Donatelli LS. 1993. Effects of thioridazine and visual screening on stereotypy and social behavior in individuals with mental retardation. Res Dev Disabil 14(3): 163-177.
162. Singh NN, Millichamp CJ. 1985. Pharmacological treatment of self-injurious behavior in mentally retarded persons. J Autism Dev Disord 15(3): 257-267.
163. Singh NN, Winton AS. 1984. Behavioral monitoring of pharmacological interventions for self-injury. Appl Res Ment Retard 5(1): 161-170.
164. SIRM (Italian Society for the study of Mental Retardation). 2003. Consensus Conference della Società Italiana per lo studio del Ritardo Mentale. Utilizzo dei farmaci antipsicotici e stabilizzatori dell'umore nel Ritardo Mentale. Italian Journal of Psychopathology 9(Suppl.): 1-16.
165. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. 2002. Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41(9): 1026-1036.
166. Sovner R. 1995. Thioridazine withdrawal-induced behavioral deterioration treated with clonidine: two case reports. Ment Retard 33(4): 221-225.
167. Sperner-Unterweger B, Czeipek I, Gaggl S, Geissler D, Spiel G, Fleischhacker WW 1998. Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine. Br J Psychiatry 172: 82-84.
168. Spivak B, Mozes T, Mester R, Kodelik M, Weizman A. 2001. Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: an open-label study. J Child Adolesc Psychopharmacol Fall 11(3): 279-284.
169. Spreat S, Conroy J. 1998. Use of psychotropic medications for persons with mental retardation who live in Oklahoma nursing homes. Psychiatr Serv 49(4): 510-512.
170. Stolker JJ, Heerdink ER, Leufkens HG, Clerkx MG, Nolen WA. 2001. Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioral disorders. Gen Hosp Psychiatry 23(6): 345-349.
171. Stolker JJ, Koedoot PJ, Heerdink ER, Leufkens HG, Nolen WA. 2002. Psychotropic drug use in intellectually disabled group-home residents with behavioural problems. Pharmacopsychiatry 35(1): 19-23.
172. Sugama S, Kusano K, Okazaki M, Eto Y. 1992. The neuroendocrinological examinations in mentally retarded boy with self-injurious behavior (SIB) and the effect of naloxone, clomipramine and sulpiride on SIB. Rinsho Shinkeigaku 32(8): 890-892.
173. Terada Y, Furuya A, Ishiyama T, Matsukawa T, Kumazawa T. 2001. Anesthetic management of a child with congenital sensory neuropathy with anhydrosis. Masui 50(7): 789-791.
174. Thalayasingam S, Alexander RT, Singh I. 2004. The use of clozapine in adults with intellectual disability. J Intellect Disabil Res 48(6): 572-579.
175. The Swedish Council on Technology Assessment in Health Care. Literature searching and evidence interpretation for assessing health care practices (SBU Report No 119E). SBU: Stockholm, 1996.
176. Timell AM. 2000. Thioridazine: re-evaluating the risk/benefit equation. Ann Clin Psychiatry 12(3): 147-151.
177. Tsiouris JA, Cohen IL, Patti PJ, Korosh WM. 2003. Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior. J Clin Psychiatry 64(9): 1081-1090.
178. Turgay A, Binder C, Snyder R, Fisman S. 2002. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110(3): 34.
179. Turner TH. 1989. Schizophrenia and mental handicap: an historical review, with implications for futher research. Psychol Med 19(2): 301-314.
180. Tyler CV, Shank JC. 1996. Dementia and Down syndrome. J Fam Pract 42(6): 619-621.
181. Ucer E, Kreger KC. 1969. A double-blind study comparing haloperidol with thioridazine in emotionally disturbed, mentally retarded children. Curr Ther Res Clin Exp 11(5): 278-283.
182. Ucer E. 1968. Chlorpromazine and thioridazine in severe mental deficiency. Mich Med 67(5): 330-332.
183. Umansky R, Geller V. 2000. Olanzapine treatment in an organic hallucinosis patient. Int J Neuropsychopharmacol 3(1): 81-82.
184. Vaisanen K, Kainulainen P, Paavilainen MT, Viukari M. 1975. Sulpiride versus chlorpromazine and placebo in the treatment of restless mentally subnormal patients-a double-blind cross-over study. Curr Ther Res Clin Exp 17(2): 202-205.
185. Vaisanen K, Viukari M, Rimon R, Raisanen P. 1981. Haloperidol, thioridazine and placebo in mentally subnormal patients-serum levels and clinical effects. Acta Psychiatr Scand 63(3): 262-271.
186. Van Bellinghen M, De Troch C. 2001. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol Spring 11(1): 5-13.
187. van Hemert JC. 1975. Pipamperone (Dipiperon, R3345) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long-term follow-up. Acta Psychiatr Scand 52(4): 237-245.
188. van Marum RJ, Jansen S, Ponssen HH. 2003. Antipsychotic medication as a cause of deep hypothermia. Ned Tijdschr Geneeskd 47(25): 1201-1204.
189. Vanden Borre R, Vermote R, Buttiens M, et al. 1993. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 87(3): 167-171.
190. Waites L, Keele DK. 1963. Fluphenazine in management of disturbed mentally retarded children. Dis Nerv Syst 24: 113-114.
191. Ward MR, Corbett JA. 1989. Neuroleptic malignant syndrome with hypomania and mental retardation. J Ment Defic Res 33(4): 339-342.
192. Weir TW, Kernohan GA, MacKay DN. 1968. The use of pericyazine and chlorpromazine with disturbed mentally subnormal patients. Br J Psychiatry 114(506): 111-112.
193. White TJ, Aman MG. 1985. Pimozide treatment in disruptive severely retarded patients. Aust N Z J Psychiatry 19(1): 92-94.
194. Williams H, Clarke R, Bouras N, Martin J, Holt G. 2000. Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability. J Intellect Disabil Res 44(2): 164-469.
195. Yamauchi K, Baba K, Ikegami N, Miyaoka H, Kamijima K. 1998. A survey of drug utilization in psychiatric hospitals in Japan: the basic analysis of the current status of prescription patterns. Seishin Shinkeigaku Zasshi 100(1): 51-68.
196. Yoo JH, Williams DC, Napolitano DA, Peyton RT, Baer DM, Schroeder SR. 2003. Rate-decreasing effects of the atypical neuroleptic risperidone attenuated by conditions of reinforcement in a woman with mental retardation. J Appl Behav Anal Summer 36(2): 245-248.
197. Yoshikawa H, Watanabe T, Abe T, Oda Y, Ozawa K. 2000. Haloperidol-induced rhabdomyolysis without neuroleptic malignant syndrome in a handicapped child. Brain Dev 22(4): 256-258.
198. Zarcone JR, Hellings JA, Crandall K, et al. 2001. Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard 106(6): 525-538.
199. Ziegler J, Behar D. 1992. Clozapine-induced priapism. Am J Psychiatry 149(2): 272-273.
200. Zuddas A, Di Martino A, Muglia P, Cianchetti C. 2000. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. Child Adolesc. Psychopharmacol Summer 10(2): 79-90.